- Home
- CUE vs HUCK Comparison
CUE vs HUCK Comparison
Compare CUE & HUCK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
SELL
Current Price
$21.97
N/A
Current Price
$3.13
Company Overview
Basic Information| Metric | CUE | HUCK |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.0M | 159.5M |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CUE | HUCK |
|---|---|---|
| Price | $21.97 | $3.13 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $88.00 | $4.17 |
| AVG Volume (30 Days) | 153.2K | ★ 726.2K |
| Earning Date | 11-11-2026 | 12-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | 31.92 |
| EPS | N/A | ★ N/A |
| Revenue | $27,466,000.00 | ★ $318,857,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 195.75 | 0.57 |
| 52 Week Low | $0.17 | $2.96 |
| 52 Week High | $45.50 | $3.55 |
Technical Indicators
Market Signals| Indicator | CUE | HUCK |
|---|---|---|
| Relative Strength Index (RSI) | 47.86 | 40.97 |
| Support Level | $17.06 | $2.99 |
| Resistance Level | $33.95 | $3.24 |
| Average True Range (ATR) | 2.33 | 0.13 |
| MACD | 0.45 | 0.01 |
| Stochastic Oscillator | 41.30 | 57.53 |
Price Performance
Historical Comparison CUE
HUCK
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.